DiaMedica Corp (DMAC): רווח נקי למניה (EPS TTM)

DMAC (DiaMedica Therapeutics) - סמל מסחרי של החברה

DiaMedica Therapeutics (DMAC) management is focused on developing therapies for brain and kidney protection. Net income per share over the trailing 12 months reflects the asset's dynamics, where -0.74 shows the current value of this metric. Growth is supported by exclusive patents and lobbying efforts in the US, while the company's development depends on clinical trial outcomes, remaining independent of macroeconomic factors.

DMAC רווח למניה ב-12 החודשים האחרונים DiaMedica Corp (04.07.2022 - 17.11.2026)

פילוחים אנליטיים ודוחות נתונים של חברת DiaMedica Pharma (DMAC)

הערכת שווי פונדמנטלית:DiaMedica Therapeutics Inc (DMAC)
סחורת הדגל של DiaMedica Therapeutics Inc

To select highly liquid assets, investors utilize filtering based on a business's ability to generate real profit per share. This metric, calculated as the ratio of net income to the number of shares, reflects capital management efficiency, which for DiaMedica Therapeutics (DMAC) will become a critical indicator of innovative drug monetization following the completion of clinical trials, based on the trailing twelve months (TTM) net income per share dynamics.